A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies

Trial Information

A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies

Inclusion Criteria:

- Patients must be 18 years of age or greater and have a histologically or
cytologically proven solid malignancy that is metastatic or unresectable and for
which standard curative or palliative measures do not exist or are no longer
effective. Patients who have recurred after previous surgery and/or radiation may
participate in this trial, although no restriction is placed on the number of prior
therapies. Patients must be willing and able to have two core-needle biopsies of
their tumor to participate in this trial.

- Patients with known brain metastases are eligible for this clinical trial if their
disease has been treated and they are clinically stable (based on the assessment of
their treating physician) and documented by a stable or improved pretreatment CT or
MRI scan of the brain to evaluate for CNS disease within 28 days prior to
registration.

- Patients may have measurable OR non-measurable disease documented by CT, MRI, X-ray
or nuclear exam (FDG-PET). All disease must be assessed within 28 days prior to
registration. Pleural effusions, ascites and laboratory parameters are not
acceptable as the only evidence of measurable disease.

- Patients must have progressed after at least one prior chemotherapy and not be
candidates for salvage surgery. Prior biologic therapy or prior radiation is
permitted; however, at least two weeks must have elapsed since the completion of
prior therapy and patients must have recovered from all associated toxicities (due to
prior therapy) at the time of registration.

- At least three weeks must have elapsed since surgery (thoracic or other major
surgeries) and patients must have recovered from all associated toxicities at the
time of registration.

- Patients must have acceptable organ and marrow function documented within seven days
of registration and as defined below:

- Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of
<2.

- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
Stage I or II cancer from which the patient is currently in complete remission or
other cancer from which the patient has been disease-free for 3 years.

- Pregnant or nursing women may not participate in this trial because of the increased
risk of fetal harm including fetal death from the chemotherapeutic agents. In order
to participate in this trial, women / men of reproductive potential must agree to use
an effective contraceptive method (hormonal or barrier method of birth control;
abstinence) prior to study entry and for the duration of study participation. Should
a woman become pregnant or suspect she is pregnant while participating in this study,
she should inform her treating physician immediately. Women of childbearing
potential must have a negative serum pregnancy test documented within seven days of
registration.

- Patients must be informed of the investigational nature of this study and must sign
and provide a written informed consent in accordance with institutional and federal
guidelines.

- Patients must have a life expectancy of greater than 12 weeks.

- Eligibility of patients receiving any medications or substances known to affect or
with the potential to affect the activity or pharmacokinetics of AR-67 will be
determined following review of their case by the Principal Investigator. Efforts
should be made to switch patients taking drugs that are strong inducers of the enzyme
CYP3A4 including anticonvulsants (i.e., phenytoin, phenobarbital, carbamazepine, or
primidone) and rifampin OR strong inhibitors of CYP3A4 (clarithromycin, itraconazole,
and ketoconazole) to other appropriate medications

Exclusion Criteria:

- Patients must not have had chemotherapy or radiotherapy within 3 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study.

- History of ≥ Grade 3 allergic reactions attributed to compounds of similar chemical
or biologic composition to AR-67 (i.e. camptothecins such as irinotecan, topotecan or
others of this class of pharmaceuticals).

- Patients with prior anaphylactic injection reaction of > Grade 3 to paclitaxel or any
other product formulated with Cremophor.

- Pregnant women are excluded from this study because AR-67 is a camptothecin with the
potential for teratogenic or abortifacient effects. Because there is an unknown but
potential risk for adverse events in nursing infants secondary to treatment of the
mother with AR-67, breastfeeding should be discontinued if the mother is treated with
AR-67.

- HIV-associated symptoms may preclude accurate assessment of toxicity or response to
the treatment and because the primary endpoint of this Phase I trial is toxicity,
patients with HIV disease will be ineligible for participation. HIV-positive
patients on combination antiretroviral therapy are ineligible because of the
potential for pharmacokinetic interactions with AR-67. In addition, these patients
are at increased risk of lethal infections when treated with marrow-suppressive
therapy and are ineligible for enrollment on this study.

- Subjects with leukemia or primary brain tumors are excluded from this study.

Type of Study:

Study Design:

Outcome Measure:

To evaluate the feasibility of obtaining two serial tumor biopsies and plasma pharmacokinetics for the determination of AR-67 half life in tumor and plasma during day 1 of AR-67 treatment given on days 1, 4, 8, 12 and 15 of an every 21-day cycle.

Outcome Time Frame:

Cycle 1 days 1 and 2

Safety Issue:

No

Principal Investigator

Susanne M Arnold, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Lucille P. Markey Cancer Center at University of Kentucky

Authority:

United States: Food and Drug Administration

Study ID:

09-MULTI-09-MCC

NCT ID:

NCT01202370

Start Date:

September 2010

Completion Date:

July 2011

Related Keywords:

Solid Malignancies

Cancer

Tumors

Neoplasms

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.